Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2018
At a glance
- Drugs Somapacitan (Primary)
- Indications Somatotropin deficiency
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 01 Jun 2018 Status changed from active, no longer recruiting to completed.
- 13 Apr 2018 Planned primary completion date changed from 25 Apr 2018 to 16 May 2018.
- 13 Apr 2018 Status changed from recruiting to active, no longer recruiting.